JOHN ANOOSHIAN: Open Payments
NPI 1235189705 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$153,651 in 361 payments from 12 companies in 2025. Trend: 2023 $129,851 · 2024 $201,696 · 2025 $153,651
Speaker / faculty: $108,511Travel & lodging: $25,260Consulting: $11,903Food & beverage: $7,977
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 103 | $60,396 |
| Janssen Pharmaceuticals, Inc | 123 | $55,179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 68 | $34,949 |
| E.R. Squibb & Sons, L.L.C. | 24 | $1,903 |
| Otsuka America Pharmaceutical, Inc. | 18 | $347 |
| Alkermes, Inc. | 11 | $273 |
| ABBVIE INC. | 6 | $181 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $131 |
| Teva Pharmaceuticals USA, Inc. | 4 | $92 |
Products named: INGREZZA, INVEGA SUSTENNA, CAPLYTA, COBENFY, ARISTADA, ABILIFY ASIMTUFII, VRAYLAR, LUMRYZ.
Industry payments across NV — which companies pay providers there.
